瑞典富吉瑞必欧Fujirebio Diagnostics  www.fdi.com www.fujirebio.co.jp
富吉瑞必欧Fujirebio是一家卓越的癌症诊断公司，和癌症生物标记检测领域的领导者。富吉瑞必欧Fujirebio致力于为人体疾病状况管理研发、制造和销售体外诊断工具，主要方向是肿瘤学领域。富吉瑞必欧Fujirebio为日本Miraca Holdings, Inc.的旗下的一家集团公司。2005年7月，领先的体外诊疗公司Fujirebio Inc.与日本一流的临床试验服务供应商SRL, Inc合并成立富吉瑞必欧。富吉瑞必欧Fujirebio的分销网络覆盖全球，为全世界的医生和患者提供诊断产品。

康乃格诊断产品（北京）有限公司
CanAg (Beijing) Technical Consulting Service Ltd.
Room 1151, Hotel Nikko New Century Beijing Office Tower Building,
No.6 Southern Road Capital Gym, Haidian District, Beijing, China
Post code: 100044
Tel: +86 10 8528 8156 68492672
Fax: +86 10 8528 8382
canag@canag.com.cn

Fujirebio Diagnostics, Inc. is a world leader in the production of in vitro diagnostics, and biomarkers. The name Fujirebio (pronounced Fuji-Ray-Bee-Oh) symbolizes restoration of health. Our parent company, Fujirebio, Inc., a leading healthcare company in Japan with a focus on diagnostics, acquired Fujirebio Diagnostics in 1998. In June 2006, CanAg Diagnostics of Sweden, now called Fujirebio Diagnostics AB joined Fujirebio Diagnostics to strengthen the company's product offerings, distribution network, and research and development capabilities. In April 2008, American Biological Technologies, Inc. became a part of Fujirebio Diagnostics. The expertise and capabilities of this site allow Fujirebio Diagnostics the versatility to continue to meet the needs of the diagnostics industry and our partners to enter the field of diagnostics outside of oncology, through the manufacture of calibrators and controls for many disease states.
Fujirebio Diagnostics specializes in the manufacturing of manual assay products, reagents and controls distributed throughout the U.S. and around the world, as well as custom-developed products for use through our worldwide network of distribution partners. With close to 65,000 square feet of manufacturing space between our U.S. headquarters in Malvern, PA, Seguin, TX, and Sweden, Fujirebio Diagnostics' proven manufacturing process has made us a global partner of choice among leading diagnostic companies.
Looking forward, we will remain committed in our efforts to deliver quality and value with products that have made us the standard of excellence in the industry and we will continue to use our resources to develop new, innovative products that aid healthcare professionals in the treatment of human disease.